Literature DB >> 16443726

The NHS breast screening programme (pathology) EQA: experience in recent years relating to issues involved in individual performance appraisal.

D M Parham1, D Coleman, S Kodikara, S Moss, I O Ellis, S Al-Sam, N Anderson, L Bobrow, I Buley, C E Connolly, N S Dallimore, S Hales, A Hanby, S Humphreys, F Knox, J Lowe, J Macartney, R Nash, J Patnick, S E Pinder, C M Quinn, A J Robertson, J Shrimankar, R A Walker, C Wells, R Winder, N Patel.   

Abstract

BACKGROUND: The original role of the National Health Service breast screening programme (pathology) external quality assessment (EQA) scheme was educational; it aimed to raise standards, reinforce use of common terminology, and assess the consistency of pathology reporting of breast disease in the UK. AIMS/
METHODS: To examine the performance (scores) of pathologists participating in the scheme in recent years. The scheme has evolved to help identify poor performers, reliant upon setting an acceptable cutpoint. Therefore, the effects of different cutpoint strategies were evaluated and implications discussed. RESULTS/
CONCLUSIONS: Pathologists who joined the scheme improved over time, particularly those who did less well initially. There was no obvious association between performance and the number of breast cancer cases reported each year. This is not unexpected because the EQA does not measure expertise, but was established to demonstrate a common level of performance (conformity to consensus) for routine cases, rather than the ability to diagnose unusual/difficult cases. A new method of establishing cutpoints using interquartile ranges is proposed. The findings also suggest that EQA can alter a pathologist's practice: those who leave the scheme (for whatever reason) have, on average, marginally lower scores. Consequently, with the cutpoint methodology currently used (which is common to several EQA schemes) there is the potential for the cutpoint to drift upwards. In future, individuals previously deemed competent could subsequently be erroneously labelled as poor performers. Due consideration should be given to this issue with future development of schemes.

Entities:  

Mesh:

Year:  2006        PMID: 16443726      PMCID: PMC1860311          DOI: 10.1136/jcp.2004.025619

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  6 in total

1.  Designing and Evaluating Standard-Setting Procedures for Licensure and Certification Tests.

Authors:  M.T. Kane; T.J. Crooks; A.S. Cohen
Journal:  Adv Health Sci Educ Theory Pract       Date:  1999       Impact factor: 3.853

2.  Reproducibility of histological diagnosis of breast lesions: results of a panel in Italy.

Authors:  D Palli; M Galli; S Bianchi; G Bussolati; S Di Palma; V Eusebi; M Gambacorta; M Rosselli Del Turco
Journal:  Eur J Cancer       Date:  1996-04       Impact factor: 9.162

3.  Impact of a national external quality assessment scheme for breast pathology in the UK.

Authors:  I O Ellis; D Coleman; C Wells; S Kodikara; E M Paish; S Moss; S Al-Sam; N Anderson; L Bobrow; I Buley; C E Connolly; N S Dallimore; S Hales; A Hanby; S Humphreys; F Knox; J Lowe; J Macartney; R Nash; D Parham; J Patnick; S E Pinder; C M Quinn; A J Robertson; J Shrimankar; R A Walker; R Winder
Journal:  J Clin Pathol       Date:  2006-02       Impact factor: 3.411

4.  Is there still a need for the general surgical pathologist?

Authors:  J C Watts
Journal:  Am J Clin Pathol       Date:  1996-10       Impact factor: 2.493

5.  Subspecialization in pathology. A European perspective.

Authors:  J Prat
Journal:  Am J Clin Pathol       Date:  1996-10       Impact factor: 2.493

6.  Subspecialization of surgical pathology at the Massachusetts General Hospital.

Authors:  W S Black-Schaffer; R H Young; N L Harris
Journal:  Am J Clin Pathol       Date:  1996-10       Impact factor: 2.493

  6 in total
  3 in total

1.  Consistency in recognizing microinvasion in breast carcinomas is improved by immunohistochemistry for myoepithelial markers.

Authors:  G Cserni; C A Wells; H Kaya; P Regitnig; A Sapino; G Floris; T Decker; M P Foschini; P J van Diest; D Grabau; A Reiner; J DeGaetano; E Chmielik; A Cordoba; X Andreu; V Zolota; E Charafe-Jauffret; A Ryska; Z Varga; N Weingertner; J P Bellocq; I Liepniece-Karele; G Callagy; J Kulka; H Bürger; P Figueiredo; J Wesseling; I Amendoeira; D Faverly; C M Quinn; S Bianchi
Journal:  Virchows Arch       Date:  2016-01-27       Impact factor: 4.064

2.  External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds.

Authors:  Ellen Bellon; Marjolijn J L Ligtenberg; Sabine Tejpar; Karen Cox; Gert de Hertogh; Karin de Stricker; Anders Edsjö; Vassilis Gorgoulis; Gerald Höfler; Andreas Jung; Athanassios Kotsinas; Pierre Laurent-Puig; Fernando López-Ríos; Tine Plato Hansen; Etienne Rouleau; Peter Vandenberghe; Johan J M van Krieken; Elisabeth Dequeker
Journal:  Oncologist       Date:  2011-03-26

3.  Technical Factors Affecting Ultrasound Breast Tumor Size as Correlated with Pathological Type.

Authors:  Eman Ahmed Shawky Sabek; Hala Taha Salem
Journal:  Medicina (Kaunas)       Date:  2019-10-25       Impact factor: 2.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.